MNOV | MediciNova, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.2500 - 2.3392
52 Week Range	1.1200 - 2.5500
Beta	0.81
Implied Volatility	237.38%
IV Rank	79.24%
Day's Volume	43,845
Average Volume	80,403
Shares Outstanding	49,046,200
Market Cap	113,473,288
Sector	Healthcare
Industry	Biotechnology
IPO Date	2006-12-08

Valuation
Profitability
Growth
Health
P/E Ratio	-11.02
Forward P/E Ratio	N/A
EPS	-0.21
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	13
Country	USA
Website	MNOV

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

MNOV's peers: ACIU, ANTX, ARTL, AUTL, NTRB, CDXC, CELC, CLGN, CLNN, CSBR, DBVT, DYAI, FENC, FHTX, GANX, GHRS, GLSI, GNFT, GNTA, HCWB, HOWL, HUMA, ICCC, IKNA, IMNM, IOBT, IPHA, JANX, DRTS, KTTA, KZIA, LBPH, AVTE, ADAG, ACRV, RZLT, ELYM, MOLN, CYT, ANEB, PMVP, PHVS, PEPG, NAUT, OMGA, OPT, PRTC, QSI, RLYB, SEER, SLGL, THTX, XLO, HLVX, DOMH

*Chart delayed

Analyzing fundamentals for MNOV we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see MNOV Fundamentals page.

Watching at MNOV technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on MNOV Technicals page.